TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06033859

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical measurements
Description: With the aid of a periodontal probe, the incidence of BOP, as well as PD, recession and KM will be assessed.

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical measurements
Description: With the aid of a periodontal probe, the incidence of BOP, as well as PD, recession and KM will be assessed.

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical measurements
Description: With the aid of a periodontal probe, the incidence of BOP, as well as PD, recession and KM will be assessed.

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical measurements
Description: With the aid of a periodontal probe, the incidence of BOP, as well as PD, recession and KM will be assessed.

Intervention type: DIAGNOSTIC_TEST
Intervention: Radiographic measurement
Description: A standardized periapical radiograph of the implant will be completed at the beginning and the end of study to determine the marginal bone loss.

Intervention type: DIAGNOSTIC_TEST
Intervention: Radiographic measurement
Description: A standardized periapical radiograph of the implant will be completed at the beginning and the end of study to determine the marginal bone loss.

Intervention type: DIAGNOSTIC_TEST
Intervention: Radiographic measurement
Description: A standardized periapical radiograph of the implant will be completed at the beginning and the end of study to determine the marginal bone loss.

Intervention type: DIAGNOSTIC_TEST
Intervention: Radiographic measurement
Description: A standardized periapical radiograph of the implant will be completed at the beginning and the end of study to determine the marginal bone loss.

Intervention type: PROCEDURE
Intervention: Dental prophylaxis or maintenance
Description: Dental prophylaxis or maintenance will be performed every 3 months.
Study: NCT06493929

Intervention type: OTHER
Intervention: Chest ultrasound
Description: to assess diaphragmatic excursion (DE(. M-mode was used to record the movement of the diaphragm during tidal breathing when the sampling line and diaphragm were as vertical as possible (not \< 70°). The data was measured from the first respiratory cycle at 0 min after SBT.

Intervention type: OTHER
Intervention: Calculation of Mechanical Power on the first day of intubation and before First trial of weaning:
Description: Total respiratory rate (RR). Positive end-expiratory pressure (PEEP) (the external or applied PEEP) recorded, not the total PEEP, or intrinsic PEEP. The plateau pressure (Pplat) was measured during an inspiratory pause on the ventilator. Peak inspiratory pressure (Ppeak) should be obtained while the patient is relaxed, not coughing or moving in bed. MP was calculated according to Gattinoni's simplified mechanical power equation as follows (3,8):~MP(J/min)=0.098×VT×RR×(Ppeak-0.5×ΔP).
Study: NCT06583837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib
Description: Orelabrutinib was administrated for 12 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: response-adapted radiation
Description: response-adapted ultra-low dose 4Gy radiation
Study: NCT04939428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molnupiravir
Description: Four molnupiravir 200 mg capsules taken by mouth.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule matched to molnupiravir 200 mg capsules taken by mouth.
Study: NCT04517851

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05930756

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: Genicular radiofrequency ablation uses thermal energy to percutaneously create lesions in neural tissues of the genicular nerves that innervate the anterior knee capsule and disrupt the conduction of pain signals.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: Genicular radiofrequency ablation uses thermal energy to percutaneously create lesions in neural tissues of the genicular nerves that innervate the anterior knee capsule and disrupt the conduction of pain signals.
Study: NCT06033859

Intervention type: PROCEDURE
Intervention: Dental prophylaxis or maintenance
Description: Dental prophylaxis or maintenance will be performed every 3 months.

Intervention type: PROCEDURE
Intervention: Dental prophylaxis or maintenance
Description: Dental prophylaxis or maintenance will be performed every 3 months.

Intervention type: PROCEDURE
Intervention: Dental prophylaxis or maintenance
Description: Dental prophylaxis or maintenance will be performed every 3 months.
Study: NCT06638593

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MIRRORS-FROZEN Protocol.
Description: Initial laparoscopic phase and thorough inspection of the abdomino-pelvic cavity to determine the feasibility of proceeding robotically, followed by robotic excision of the mass(es) and its retrieval in a bag if deemed suitable to proceed robotically. The mass or cyst will be sent for frozen section to determine the extent of the surgery. The surgery will continue robotically, with conversion to laparotomy considered at any point at the discretion of the individual surgeon.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard open surgery
Description: A midline abdominal incision will be made from the outset, with intraoperative frozen section assessment to determine the extent of the surgery.
Study: NCT04709393

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FRAX+SARC-F questionnaire pre-screening
Description: Pre-screening group participants will receive the FRAX+SARC-F questionnaire pre-screening and be notified of the preliminary estimation of their future hip fracture risk before being invited to our DXA screening and fall-risk assessment.
Study: NCT06636825

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graded hypercapnia
Description: Volunteers breathe 0%, 2%, 4%, 6%, and 8% CO2 (with 21% O2, balance nitrogen) for 12 minutes each

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Graded hypercapnia
Description: Volunteers breathe 0%, 2%, 4%, 6%, and 8% CO2 (with 21% O2, balance nitrogen) for 12 minutes each

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: 400 mg caffeine capsule taken in a single dose 1 hour prior to graded hypercapnia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (microcrystalline cellulose) capsule taken in a single dose 1 hour prior to graded hypercapnia
Study: NCT06637735

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: education
Description: pregnant women will be given a 4-week training and the pre-test post-test will be analyzed
Study: NCT06049160

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: All participants will be assigned for giving misoprostol rectally either preoperative or postoperative

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: All participants will be assigned for giving misoprostol rectally either preoperative or postoperative
Study: NCT06641752

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood drop sampling
Description: The process: blood drop sampling Technique: capillary sampling Frequency: Once Time: 5 minutes Sample collection volume: 1mL Total collection volume: 1 mL
Study: NCT05247866

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Eosinophilic Esophagitis (EoE) food introduction-1st
Description: 1 serving size of food proven to induce histologic and clinical symptoms in EoE

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Eosinophilic Esophagitis (E0E) food introduction-2nd
Description: Either 1 serving size of different food (not food in arm 1) to induce histologic and clinical symptoms in EoE or Increase the food in arm 1 to 2 serving size a day
Study: NCT04812470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous Tumor Infiltrating Lymphocytes
Description: Administered via hepatic arterial infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan will be administered once as an intravenous infusion.
Study: NCT05247866

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Eosinophilic Esophagitis (EoE) Food introduction-3rd dose
Description: Either 1 serving size of different food (not food in arm 1 or 2) to induce histologic and clinical symptoms in EoE or Increase the food in arm 2 to 2 serving size a day or unlimited amounts of food arm 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: All patients will receive open label dupilumab at the following doses \>12 years of age \> 40 kg 300 subcutaneous (SQ) weekly~6-11 years of age 5-15 kg 100 mg SQ every 2 weeks (Q2W) 15-30 kg 200 mg SQ Q2W \>30-60 kg 300 mg SQ Q2W
Study: NCT05960435

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation
Description: PNF, a method used to increase the range of motion of the joint and strengthen the muscles in the newly gained range, is a holistic approach and is based on motor learning principles. PNF stretching involves isometric contraction of the target muscle in addition to static stretching.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group Exercise
Description: The control group will include static stretching, capsule stretching, progressive ROM exercises and strengthening exercises.
Study: NCT04833075

Intervention type: OTHER
Group type: OTHER
Intervention: blood sampling
Description: A maximum of 13 blood samples (39 mL) will be derived from subjects on treatment. After discontinuation of ICI treatment, a maximum of 7 blood samples (21 mL) will be derived.
Study: NCT06512818

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Psiguavin
Description: A purified guava extract will be used, enriched in psiguavin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules with the same characteristics that Psiguavin intervention but filled with a placebo compound
Study: NCT04812470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: After TIL infusion, Interleukin-2 will be administered subcutaneously once daily for up to 14 days.
Study: NCT06204666

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Dose Hemp Fiber Bar
Description: High dose hemp fiber bar with other ingredients
Study: NCT04669678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etonogestrel (ETG) implant
Description: Contraceptive progestin implants are thin rods inserted under the skin of a woman's arm. The most widely available implant in South Africa is currently Implanon®/Nexplanon®/Implanon NXT®, containing etonogestrel (ETG, 3-keto desogestrel). Implanon® consists of a single rod of ethylene vinyl acetate and contains 68 mg of ETG; it is manufactured by Merck and is approved for 3 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intramuscular depo-medroxyprogesterone acetate (IM DMPA)
Description: DMPA (150 mg of depo-medroxyprogesterone acetate (MPA)/ml IMI) is the most commonly used injectable contraceptive worldwide, and the most commonly used method of reversible injectable contraception in sub-Saharan Africa.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular depo-medroxyprogesterone acetate (IM DMPA)
Description: DMPA (150 mg of depo-medroxyprogesterone acetate (MPA)/ml IMI) is the most commonly used injectable contraceptive worldwide, and the most commonly used method of reversible injectable contraception in sub-Saharan Africa.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sub-cutaneous medroxyprogesterone acetate (SC MPA)
Description: SC MPA or Sayana® Press is a single-dose container with 104 mg medroxyprogesterone acetate (MPA) in 0.65 mL suspension for injection. Sayana® Press is indicated for medium-long term female contraception.
Study: NCT05041699

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: IPM Ring-105
Description: DPV-LNG Ring containing xx mg of dapivirine + xx mg of levonorgestrel

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: IPM Ring-106
Description: DPV-LNG Ring containing xx mg of dapivirine + xx mg of levonorgestrel
Study: NCT06138158

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise and Education Group
Description: Physical exercise and pain education
Study: NCT05516147

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SAFE at Home
Description: SAFE at Home will enable community-dwelling PWD to participate in videoconference-based group activities with their peers, that is, other PWD. SaH sessions will be facilitated by highly trained Engagement Professionals.
Study: NCT04508530

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panzyga
Description: Panzyga 10% IVIG
Study: NCT04669678

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-hormonal intrauterine device (IUD)
Description: The NOVA T-380 non-hormonal IUD consists of a T-shaped polyethylene frame wound with copper wire, along with two monofilament threads to aid in removal of the IUD. IUDs may be left in place for up to 5 years.
Study: NCT04508530

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06199882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBRT Sequential Surufatinib Combined With Immunotherapy
Description: 1. SBRT :~   Bioequivalent total dose \> 75Gy, completed within 2 weeks (once daily, 5 times a week).~2. Drug treatment (every 3 weeks is a treatment cycle) :~1) Surufatinib: 200 mg, po, qd, taken continuously; 2) Carrelizumab: 200 mg/ time, intravenous drip on the first day of each cycle.
Study: NCT06640504

Intervention type: DIAGNOSTIC_TEST
Intervention: serum albumin
Description: Serum albumin ratios were calculated as the ratio between the estimated blood lactate, and serum levels of CRP and PCT divided by the estimated serum albumin level to get the lactate-to-albumin ratio (LAR), CRP-to-albumin ratio (CAR) and procalcitonin (PCT)-to-albumin ratio (PAR).

Intervention type: DIAGNOSTIC_TEST
Intervention: C-Reactive Protein
Description: The serum levels of C-reactive protein (CRP) are divided by the estimated serum albumin level to get the CRP-to-albumin ratio (CAR).

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum procalcitonin
Description: The serum levels of procalcitonin (PCT) are divided by the estimated serum albumin level to get the PCT-to-albumin ratio (PAR).

Intervention type: DRUG
Intervention: Blood Lactate
Description: The serum levels of blood lactate are divided by the estimated serum albumin level to get the lactate-to-albumin ratio (LAR).
Study: NCT06637475

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric stimulation
Description: Patients with baseline assessments will be followed up for 8 weeks within a planned treatment program. Treatment protocol for the ES group:~external ES wearable apparatus will be applied three days a week for 30 minutes with symmetrical biphasic current at a frequency of 50 Hertz (Hz), with stimulation and rest periods of 5 s contraction and 5 s rest, with a current intensity ranging from 0-100 mA while the patients are in the supine position. The device will be attached to the patients in such a way that it wraps around the upper thigh, the electrodes will be attached to the anterior and posterior of the right and left thigh, the right-left pelvic side and the right-left gluteal region. The current intensity in each session will be determined as the maximum current intensity that will not cause pain and discomfort in individuals.
Study: NCT06640452

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RecoveryFun system
Description: The system components were: VR headset; wereable biosensors, clinical platform, caregiver app and smart services.
Study: NCT06637852

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SUFICS-PACT
Description: SUFICS-PACT includes sexual and urinary dysfunction screening, collaborative treatment of sexual and urinary dysfunction, and care managers who are mental health professionals with training in psychosexual counseling. Mental health professionals will facilitate a comprehensive approach to sexual dysfunction, as emphasized by the biopsychosocial model of sexual health. SUFICS-PACT also emphasizes close follow up, which is important for sexual function recovery after prostate cancer treatment.
Study: NCT06638021

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted EHR-based Communication of Diagnostic Uncertainty (TECU)
Description: The Targeted EHR-based Communication about Uncertainty (TECU) strategy will be activated in the electronic health record (Epic) every time an ED clinician enters an uncertain diagnosis for a patient being discharged, and will notify the clinician to counsel the patient about uncertainty while additionally triggering automated 1) insertion and printing of the patient handout and 2) provision of a hyperlink for the clinician-facing checklist to guide the discharge conversation.
Study: NCT06636812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan potassium
Description: Single dose losartan (25mg or 50 mg, weight-adjusted), encapsulated identically to placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single tablet encapsulated identically to placebo
Study: NCT06638086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen Suppositories
Description: Per rectal suppositories

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen Injection
Description: Intra-venous injection
Study: NCT06641024

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MC-1-50
Description: A single infusion of CD19 CAR-T cells will be administered intravenously after lymphodepletion chemotherapy
Study: NCT06639113

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-administration medicines
Description: Management of drugs' administration by the patient
Study: NCT06644482

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise group in a hospital setting
Description: Participants will exercise in a group once a week for 16 weeks in a hospital setting.
Study: NCT06577441

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo buccal swab and blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo buccal swab and blood sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study: NCT05359328

Intervention type: DEVICE
Group type: OTHER
Intervention: Pulse Oximeter, Respiratory Rate, Heart Rate and Arterial line
Description: Measurement of physiological parameters
Study: NCT05861427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atogepant
Description: Oral Tablet
Study: NCT06577441

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decitabine and Cedazuridine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine and Cedazuridine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib
Description: Given PO
Study: NCT05746273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Nicotine Patch
Description: Participants will wear nicotine transdermal patches daily for 12-15 weeks. They will apply a study patch each morning and remove at bedtime. Active dose will titrate up from 3.5mg to 7mg, and then can optionally be further titrated to a maximum dose of 14mg. After week12, the dose will be slowly tapered over 2-3 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Transdermal Placebo Patch
Description: Participants will wear placebo transdermal patches daily for 12-15 weeks. They will apply a study patch each morning and remove at bedtime. Placebo patch dose will titrate up from 3.5mg to 7mg, and then can optionally be further titrated to a maximum dose of 14mg. After week12, the dose will be slowly tapered over 2-3 weeks.
Study: NCT06375499

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: T2769
Description: Daily dose regimen: 1 drop in each eye, from 3 to 6 times daily.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hylo-Forte®
Description: Daily dose regimen: 1 drop in each eye, from 3 to 6 times daily.
Study: NCT06545903

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LMA Supreme
Description: The device is inserted and the manikin ventilated

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SLIPA
Description: The device is inserted and the manikin ventilated

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I-gel
Description: The device is inserted and the manikin ventilated

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AuraGain
Description: The device is inserted and the manikin ventilated
Study: NCT05861427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atogepant
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atogepant
Description: Oral Tablet
Study: NCT06405347

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inpatient Whole Health Bundle
Description: Hospitalized patients on the intervention units will be offered participation in the Inpatient Whole Health Bundle, which is comprised of a variety of offerings aimed at improving the wellbeing of the patient. They can choose to use any or none of the bundle elements.
Study: NCT04620668

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wysa
Description: Wysa is an AI-based mental health chatbot. It uses evidence-based techniques to help users build mental resilience skills and improve their mental health.
Study: NCT05861427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atogepant
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Atogepant
Description: Oral Tablet
Study: NCT05960201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]fluoroestradiol (FES)
Description: F-18 FES 111\~222 MBq(megabecquerel) injection
Study: NCT06569095

Intervention type: OTHER
Intervention: Detection of MDS-SC using MFC
Description: The aim of this study is to investigate the predictive values of MDS-SC determined by MFC for patients with MDS-EB who underwent allotransplantation.